Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
Company to provide a detailed overview of its norovirus clinical program
Webcast to be held on March 28, 2023 at 1:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host a key opinion leader video webcast on the health and economic impact and disease burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.
The webcast will feature presentations by prominent norovirus disease experts Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Centers for Disease Control & Prevention, and Sarah Bartsch, Project Director, Public Health Informatics, Computational, and Operations Research, Research Foundation of the City University of New York.
In addition, Vaxart management will provide a detailed overview of the Company’s investigational norovirus oral pill vaccine program, including its two current Phase 2 clinical trials:
About the KOLs
Jan Vinjé, Ph.D.
Sarah M. Bartsch, MPH
Note Regarding Forward-Looking Statements
Please also refer to the risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.